Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

Summary

Phase 2, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of daxdilimab in patients with active, proliferative lupus nephritis (LN).

Timeline

Start

2023-04-26

Primary completion

2024-01-04

Completion

2024-01-04

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision”

Drugs

Indications